Evidence map›Paper›PMID 40167906›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Recent Advances in Human Cerebrospinal Fluid Proteomics.

Joaquín Fernández-Irigoyen, Enrique Santamaría

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joaquín Fernández-IrigoyenProteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
Enrique SantamaríaProteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain. esantamma@navarra.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebrospinal fluid (CSF) proteomics has become an alternative that allows zooming-in where pathophysiological alterations are taking place, detecting protein mediators that might eventually be considered as potential biomarkers in neurological or psychiatric diseases. From a technological point of view, mass-spectrometry-based-proteomics as well as antibody/aptamer-based platforms allow the simultaneous monitoring of secreted and circulating proteins in a broad concentration range in a robust manner, generating innovative facets in biomarker validation. This chapter highlights recent discoveries in the field of CSF protein analysis, covering sample preparation methods for proteomic workflows, shotgun proteomics, subproteomics, and other omics applied to CSF.

Indexed as

Cerebrospinal Fluid ProteinsProteomeProteomicsBiomarkersHumansMass SpectrometryBiomarkersCerebrospinal Fluid ProteinsProteomeAptamersHuman CSFMass spectrometryProteomics

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.